Jefferies initiates coverage on Mirati Therapeutics (NASDAQ: MRTX) with a Buy. PT $36.00.

Analyst Thomas Wei weighs in: "Mirati ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE